Treatment with DNX did not demonstrate any clinically meaningful benefit on COPD symptoms (ERS: COPD) or health-related quality of life (SGRQ) and exploration of multiple subgroups did not identify a population that could benefit from DNX treatment, contrary to an earlier study that suggested COPD patients who were current smokers might benefit from treatment with a CXCR2 antagonist [25]. Here, CXCR2 is linked to chronic obstructive pulmonary disease.